WEOS Finger Lakes Public Radio

Scott Hensley

It's not often in the midst of an antitrust fight that the public gets a look at the gamesmanship that's happening behind the scenes.

But thanks to the Huffington Post's Jonathan Cohn and Jeff Young, we got a glimpse at how health insurer Aetna is making its case to acquire rival Humana — and new insight into Aetna's decision announced Tuesday to pull out of Obamcare exchanges in 11 states.

Concussions have become part of the daily news. But how much have these brain injuries become part of daily life?

To find out, we asked people across the country about concussions in the latest NPR-Truven Health Analytics Health Poll.

The poll, conducted during the first half of March, found that nearly a quarter of people — 23 percent of those surveyed — said they had suffered a concussion at some point in their lives. Among those who said they'd had a concussion, more than three-quarters had sought medical treatment.

Republican front-runner Donald Trump released a seven-point plan to change the country's health care system that includes several familiar GOP proposals and one that puts him in agreement with, believe it or not, Democratic hopeful Bernie Sanders.

A majority of Americans say electronic cigarettes should be regulated by the Food and Drug Administration the same way the agency handles cigarettes containing tobacco, according to results from the latest NPR-Truven Health Analytics Health Poll.

Overall, 57 percent of people said the FDA should regulate e-cigarettes like tobacco products. The proportion of people in favor of regulation rose with age and education. Nearly, two-thirds of people with college degrees or graduate degrees supported regulation compared with 48 percent with high school diplomas or less.

Most women 40 and older believe they should have mammograms every year to screen for breast cancer, the latest NPR-Truven Health Analytics health poll finds.

A deal struck between drugmakers AbbVie and United Therapeutics Wednesday set a record price for a voucher that can be redeemed for a fast-track review of a new medicine by the Food and Drug Administration.

AbbVie, marketer of Humira and AndroGel, has agreed to pay $350 million to United Therapeutics, a company specializing in treatments for rare diseases, for a ticket to the regulatory fast lane.